Dr. Schul’s team shares joy that their clinical research team experience with SAVAYSA has led to FDA approval for treatment of acute deep vein thrombosis management.
Dr. Schul and his clinical team are excited to share that simpler means are becoming the standard in managing acute deep vein clots/blood clots. Frequent blood draws, watching the foods we eat, the things we drink, are simply becoming a concern of the past. SAVAYSA is one of the Xa inhibitor class of drugs. When compared head to head with traditional coumadin, non inferiority has been easily established. To consider the impact, the management of acute blood clots is extraordinary costly. Three months of a Xa inhibitor alone is far less costly than traditional management.
Remember the three tenets of blood clot management, walking, compression, and anticoagulation. Now that Xa inhibitors are here to stay, patients will find it less intrusive to be managed vs. alternative regimens. To learn more about SAVAYSA, visit http://savaysa.com.
Dr. Schul and his team manage the spectrum of venous reflux disease. If you have suffered leg pain, swelling, leg ulcers, or blood clots, we can help. Call Dr. Schul at (765) 807-2770 to schedule your appointment and see how we can improve your life.